Back HIV/Hepatitis Coinfection

Coinfection

CROI 2013: Adding Telaprevir Increases Acute Hepatitis C Cure Rate for HIV+ Men

Adding telaprevir (Incivek) to pegylated interferon and ribavirin shortens the duration of therapy and improves the likelihood of a cure for HIV positive men with acute sexually transmitted hepatitis C virus (HCV), according to study findings presented at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) last week in Atlanta.

alt

Read more:

CROI 2013: Adding Telaprevir Ups Acute Hepatitis C Cure Rate for HIV+ Men [VIDEO]

Adding telaprevir (Incivek) to pegylated interferon/ribavirin for treating HIV positive men with acute sexually transmitted hepatitis C considerably shortens the duration of therapy and improves the likelihood of a cure, according to study findings presented this week at the 20th Conference on Retroviruses and Opportunistic Infections (CROI 2013) in Atlanta.

alt

Read more:

Hepatitis C Treatment Adherence Is Important for HIV/HCV Coinfected People

Near-perfect adherence to pegylated interferon plus ribavirin offers the best chance of sustained virological response -- or a cure -- for HIV positive people coinfected with hepatitis C virus (HCV), according to a U.S. veterans study described in the August 21, 2012, advance online edition of AIDS and Behavior.

alt

Read more:

Tenofovir plus Emtricitabine or Lamivudine Does Not Always Suppress Hepatitis B in HIV/HBV Coinfected

HIV/HBV coinfected people with high hepatitis B virus (HBV) levels and those who are HBeAg positive are at greater risk of not achieving HBV suppression after a year on tenofovir plus emtricitabine or lamivudine, but most did so eventually, researchers reported in the February 21, 2013, advance online edition of AIDS.

alt

Read more:

Tenofovir Leads to HBsAg Clearance in 8% of HIV/HBV Coinfected Patients

Treatment with tenofovir (Viread) led to hepatitis B surface antigen (HBsAg) clearance -- considered the closest outcome to a cure -- in 8% of HIV positive patients with chronic hepatitis B virus (HBV) coinfection, and in a subgroup clearance was associated with CD4 T-cell count, Dutch researchers reported in the September 15, 2012, Journal of Infectious Diseases.alt

Read more:

AASLD 2012: Final Study Results Show Telaprevir Is Safe and Effective for HIV/HCV Coinfected Patients

HIV/HCV coinfected people treated with telaprevir (Incivek) triple therapy are significantly more likely to achieve sustained virological response, or a cure, than people treated with pegylated interferon/ribavirin alone, according to final results from Study 110 presented at the American Association for the Study of Liver Diseases Liver Meeting (AASLD 2012) this week in Boston.alt

Read more:

ICAAC 2012: Raltegravir Shows Long-term Safety and Efficacy for HIV/HCV and HIV/HBV Coinfection

The HIV integrase inhibitor raltegravir (Isentress) was well-tolerated and demonstrated continued effectiveness for 5 years in treatment-naive and 3 years in treatment-experienced HIV patients coinfected with hepatitis B or C, according to a poster presentation at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) last week in San Francisco.alt

Read more:

HIV+ People Who Acquire Hepatitis C May Have Impaired HCV-specific Interferon Response

People who already have HIV when they become infected with hepatitis C virus (HCV) appear to have reduced production of cytokines including natural interferons active against HCV, according to a study described in the November 15, 2012, Journal of Infectious Diseases. alt

Read more:

AIDS 2012: Triple Infection with HBV Promotes HCV Clearance in People with HIV

altCompetition between hepatitis B virus (HBV) and hepatitis C virus (HCV) in HIV positive people with triple infection appears to promote spontaneous HCV clearance, but lower CD4 T-cell counts and greater liver inflammation reduce the likelihood of clearance, Chinese researchers reported at the XIX International AIDS Conference (AIDS 2012) last month in Washington, DC.

Read more: